Serum anti-Glc(α1,4)Glc(α) antibodies as a biomarker for relapsing–remitting multiple sclerosis

Schwarz, Mikael; Spector, Larissa; Gortler, Monica; Weisshaus, Oori; Glass-Marmor, Lea; Karni, Arnon; Dotan, Nir; Miller, David H.

doi:10.1016/j.jns.2005.12.006

Cited by 57 publications

(57 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum IgG and IgM anti-CSF114(Glc) antibodies correlated with clinical activity and cerebral MRI lesions. These findings are consistent with other recent studies demonstrating an enhanced antibody response in MS patients to other glycosylated antigens such as anti-Glc (alpha1,4)Glc(alpha) [43].…”

Section: Antibodies Against Myelin Lipids and Glycopeptidessupporting

confidence: 93%

Multiple sclerosis: Disease biomarkers as indicated by pathophysiology

Berger

Reindl

2007

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Section: Antibodies Against Myelin Lipids and Glycopeptidessupporting

confidence: 93%

Multiple sclerosis: Disease biomarkers as indicated by pathophysiology

Berger

Reindl

2007

Journal of the Neurological Sciences

View full text Add to dashboard Cite

“…In some recent studies in certain disease, such as proteinase-3-associated vasculitis (47), Graves' disease (48) and multiple sclerosis (49), there appears to be a good correlation between clinical remission and marked reduction or absence of detection of pathogenic autoantibody. However, in other diseases, such rheumatoid arthritis and systemic lupus erythematosus, such distinct correlations are not always present (50,51).…”

Section: Discussionmentioning

confidence: 99%

Serological Studies in Bullous Pemphigoid: A Literature Review of Antibody Titers at Presentation and in Clinical Remission

Leuci

Gürcan²,

Ahmed³

2010

Acta Derm Venerol

View full text Add to dashboard Cite

Bullous pemphigoid is associated with antibodies to a 230 kDa and a 180 kDa protein. In a literature review we investigated the role of auto-antibodies as detected by different serological assays. Nine reports containing data on 143 patients were analyzed. Pre-treatment data showed that indirect immunofluorescence, enzyme-linked immunosorbent assay (ELISA) and immunoblotting offer an 82.2% or greater probability of being positive. At the end of the study period, all patients had clinically improved, whether or not they were on therapy. Auto-antibodies were present in 29% of patients evaluated by monkey esophagus immunofluorescence and 75% of those evaluated by human skin immunofluorescence. Positive titers were also reported in 67.6% of patients evaluated by ELISA. In 100% of patients in whom immunoblotting was performed the titers became negative. In 3 patients (5.3%) using human skin immunofluorescence and in one patient (1.4%) using ELISA the titers were increased at the end of the study period. The correlation between anti-basement membrane zone antibodies and the clinical course of bullous pemphigoid requires further and long-term studies.

show abstract

“…the probability of negative detection in the control group. A recently published method for the diagnosis of multiple sclerosis by antibody monitoring provides a good example [15] . The cutoff value for our test was pre-evaluated with a battery of stored serum samples of registered normal subjects and schizophrenic patients, and was selected as 1.3 OD units.…”

Section: Laboratory Proceduresmentioning

confidence: 99%

Blind Verification of Elevated Platelet Autoantibodies in Serum of Schizophrenic Patients – Part I: Young Subjects

Spivak¹,

Schechtman

Blumensohn³

et al. 2009

Neuropsychobiology

View full text Add to dashboard Cite

Background: It has been hypothesized that the etiology of schizophrenia, in a distinct group of patients, originates from an autoimmune reaction against platelets. Previous open screenings have recorded significantly higher blood titers of platelet-associated autoantibodies (PAA) in schizophrenic patients as compared to normal healthy subjects. In addition, young schizophrenic patients at the early stages of their disorder displayed higher PAA titers than older patients with a longer duration of the disorder. A blood test based on these observations was proposed. Aim: To verify by a blind test a significant difference in PAA between young schizophrenic patients and matched healthy control subjects, for the validation of a blood test for schizophrenia. Methods: A total of 36 young schizophrenic patients in an active psychotic state, aged 13–20 years (mean ± SD: 16.2 ± 2.1 years) with an average PANSS score of 115.6 ± 14.5 and illness duration of 9.5 ± 9.4 months, were examined. The control group consisted of 49 healthy young subjects between the ages of 13 and 21 years (16.2 ± 2.2 years). The blood titers of PAA were evaluated blindly using an optimized ELISA test, expressed by a linear optical density (OD) scale. The blood samples of all participants were tested anonymously, and were scored under a code number. A test recording above 1.3 OD units was defined as positive. Results: The PAA titers of schizophrenia patients (1.6 ± 0.4 OD units, range: 0.7–2.3 OD units) were significantly higher than those of the control group (1.0 ± 0.4 OD units, range: 0.4–1.8 OD units; p < 0.0001). In 61% of the young schizophrenic patients (22 out of the 36 patients), a positive result (OD >1.3 units) was recorded. In the control group, only 12.2% (6 of the 49 subjects) displayed a positive result (p < 0.0001). Conclusions: These findings support further assessment of PAA titers as a potential biomarker for patients with clinical signs and symptoms of schizophrenia.

show abstract

Serum anti-Glc(α1,4)Glc(α) antibodies as a biomarker for relapsing–remitting multiple sclerosis

Cited by 57 publications

References 46 publications

Multiple sclerosis: Disease biomarkers as indicated by pathophysiology

Multiple sclerosis: Disease biomarkers as indicated by pathophysiology

Serological Studies in Bullous Pemphigoid: A Literature Review of Antibody Titers at Presentation and in Clinical Remission

Blind Verification of Elevated Platelet Autoantibodies in Serum of Schizophrenic Patients – Part I: Young Subjects

Contact Info

Product

Resources

About